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Abstract
Metabolic syndrome is an epidemic of XXI century. Each of the components of metabolic syndrome (arterial hypertension,
hyperglycemia or dyslipidemia) can be a risk factor for chronic kidney disease. However, it remains unknown what plays a key
role in the progression of the disease.
The objective of the research was to identify early detectors of kidney damage in patients with metabolic syndrome.
Materials and methods. The study involved 70 patients with metabolic syndrome. In addition to standard examination
methods, markers of endothelial disfunction (hydrogen sulfide and nitrogen monooxide) were measured in venous blood
samples and the urine was tested for microalbuminuria. All the patients were divided into 3 groups according to the degree of
albuminuria: normoalbuminuria, microalbuminuria and macroalbuminuria. To compare the indices between the groups, the
Student’s t-test was used; to determine the relationship between the individual values, the Pearson correlation coefficient (r)
was applied.
Results. The indicator of systolic blood pressure was higher in patients with microalbuminuria compared to those with
normoalbuminuria (163.4±14.4 mmHg, versus 153.0±17.7 mmHg; p<0.01). Hydrogen sulfide level was higher in patients
with normoalbuminuria (66.8±7.2 µmol). There was a moderate positive correlation between systolic blood pressure and
microalbuminuria (r=0.3804; p<0.01) and a moderate negative correlation between hydrogen sulfide and microalbuminuria
(r=0.3404; p<0.01).
Conclusions. We revealed a decrease in hydrogen sulfide level to 57.4±7.9 µmol in patients with metabolic syndrome. This
may be an early predictor of kidney damage.
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Problem statement and analysis of the
recent research
Metabolic syndrome (MS) is an epidemic of XXI century.
Its prevalence in highly industrialized countries constitutes
20-30%. The main components of MS including abdomi-
nal obesity, glucose intolerance or type 2 diabetes mellitus
(T2DM), arterial hypertension (AH), dyslipidemia lead to the
development of severe cardiovascular complications [6, 8,
13].
These risk factors play a significant role in the develop-
ment of chronic kidney disease (CKD) as well. The number
of patients requiring dialysis is growing every year [1, 6, 8,
9, 11, 12]. Many epidemiological studies confirmed that MS
is an independent predictor of the occurrence of proteinuria
and CKD as well as its progression till the terminal stage [6,
8, 11-13]. This is evidenced by a correlation between MS and
known CKD markers, namely proteinuria, microalbuminuria
and glomerular filtration rate (GFR). Chronic inflammation
and insulin resistance being the main signs of MS result in the
activation of renin-angiotensin-aldosteron system, hyperfiltra-
tion and albuminuria [13-15].
Abdominal obesity is considered as the main cause of
insulin resistance, hyperglycemia, AH and dyslipidemia [5].
The increase in visceral fat from 0.5 kg to 1.8 kg leads to the
reduction in tissue sensitivity to insulin by 60% [8]. Due to
obesity, hyperfiltration and hypertrophy of podocytes further
contributing to CKD occurrence develop [5].
Kidney damage in patients with cardiovascular risk fac-
tors is associated with oxidative stress and chronic systemic
inflammation [11-13]. Hydrogen sulfide (H2S) and nitrogen
monoxide (NO) play a significant role in these processes [2,
4, 10]. Together with carbon monoxide (CO), they belong
to the family of gasotransmitters which are involved in the
regulation of the physiological functions of the cardiovascular,
nervous and digestive systems [10].
Endothelial cells release H2S and NO in response to
different stimuli including insulin, estradiol, acetylcholine,
bradykinin, endothelium growth factor (EGF) [2-4]. In 2008,
there was found that that H2S is released not only by smooth
muscle cells of the vascular wall, but also by the endothelium
[10].
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Abdominal obesity, AH, DM are accompanied by oxida-
tive stress [6, 8, 11, 12]. In hypoxia, the accumulation of
H2S in the medulla helps restore oxygen balance through
the increase in the renal circulation, the reduction in energy
requirements for Na ions transport and the inhibition of mito-
chondrial respiration. Hydrogen sulfide deficiency can lead to
progression of kidney damage in patients with comorbidities
[3]. The decrease in endogenous H2S is known to inhibit
protective vasodilatation in response to high blood pressure
(BP) as well as to provoke kidney damage [2-4, 7]. The results
of the study carried out in 2016 including 1,004 patients with
T2DM showed that high concentration of H2S correlated with
low degree of proteinuria [14]. The results of study conducted
in 2015 demonstrated that the use of hydrogen sulfide donors
in mice accelerated the recovery of the kidneys after ischemic
injury [7].
Renal dysfunction in patients with MS probably appears
long before the onset of DM and AH. Its pathogenesis has not
been studied well yet and is quite disputable. MS component
which plays the most important role in the disease progression
is still unknown.
The objective of the research was to identify early detec-
tors of kidney damage in patients with MS.
1. Materials and methods
The study involved 70 (20 men and 50 women) patients with
MS. The diagnosis of MS was made according to the Inter-
national Diabetes Federation Criteria (2015). Patients with
type 1 diabetes mellitus (T1DM), left ventricular systolic
dysfunction (EF<45%), renovascular hypertension, disorders
of the hypothalamic-hypophyseal system, thyroid disorders,
parathyroid and adrenal diseases, systemic connective tissue
disorders, urinary and oncologic diseases were excluded from
the study. All the patients underwent clinical examinations –
their complaints were recorded, a medical history was taken,
basic laboratory tests (complete blood count, urine analysis,
blood glucose test, biochemical blood assay, lipid profile) as
well as instrumental ones (electrocardiography, chest X-ray,
echocardiography and ultrasound examination of the internal
organs) were performed.
In addition, blood sample was taken from the vein for the
determination of the level of uric acid, NO (method of Sum-
baeva VV, Yasinska IM.) and H2S [15]; the urine was tested
for microalbuminuria (MAU). GFR was calculated accord-
ing to the Cockcroft–Gault (CG) and Modification of Diet in
Renal Disease (MDRD) formulas.
Kidney damage was assessed by the degree of albumin-
uria. All the patients were divided into 3 groups according to
the degree of albuminuria (the American Diabetes Associa-
tion, 2016): Group I included patients with normoalbuminuria
(<0.03 g/l), Group II included patients with microalbuminuria
(0.03 – 0.3 g/l), Group III included patients with macroalbu-
minuria (<0.3 g/l).
To compare the indices between the groups, the Student’s
t-test was used; to determine the relationship between the
individual values, the Pearson correlation coefficient (r) was
applied.
2. Results and discussion
The average age of all patients was 62.3±10.4 years. Normoal-
buminuria was detected in 18 (25.7%) patients, microalbumin-
uria was found in 35 (50.1%) patients, macroalbuminuria was
observed in 17 (24.2%) patients. All parameters are presented
in Table 1.
In patients with macroalbuminuria, body mass index (BMI)
was higher compared to patients with microalbuminuria (35.0±3.5
kg/m2; 30.5±3.8 kg/m2; p< 0.05). There was no difference
in BMI between Group I and Group II. The average waist
circumference (WC) was higher in Group II (103.3 ± 9.1 cm)
as compared to Group I (95.3±5.1 cm), p<0.001. There was
no difference in WC between Group II and Group III.
The average value of systolic blood pressure (SBP) was
higher in patients with microalbuminuria as compared to those
with normoalbuminuria (163.4±17.5 mm Hg; 153.0±14.4
mmHg; p<0.001). The average value of diastolic blood pres-
sure (DBP) was higher in Group III as compared to Group II
(105.1±10.5 mm Hg; 97.2±8.9 mmHg; p<0.001).
The level of triglycerides (TG) was higher in Group III
as compared to Group I (2.8±0.8 mmol/l; 2.2±0.7 mmol/l;
p<0.05). The concentration of H2S was higher in Group I
as compared to Group III and Group III (66.3±5.7 µmol;
62.2±7.9 µmol; 57.4 ±7.9 µmol; p<0.05, p<0.01).
There was no difference in the indicators of lipid profile,
GFR and NO between groups.
There was a moderate positive correlation between SBP
and MAU (r=0.3804; p<0.01) and a moderate negative cor-
relation between H2S and MAU (r= -0.34042; p<0.01); the
same correlation was observed between SBP and MAU (r=-
0.4443; p <0.01) (Fig.1).
Thus, a decrease in H2S level leads to the increase in SBP
which in turn increases the degree of MAU.
Having analyzed the aforementioned results, we can state
that among all the components of MS, increased BP is the
most harmful for the kidneys. The difference in this indicator
between patients with normoalbuminuria and those with mi-
croalbuminuria indicates that even slight BP fluctuations lead
to impaired renal function. Correlation between H2S, MAU
and SBP proves that endothelial dysfunction is involved in
its pathogenesis. The obtained results are consisted with the
results of other authors, who indicated that low H2S concen-
tration correlated with high degree of proteinuria [14].
Conclusions
We revealed a decrease in hydrogen sulfide level to 57.4±7.9
µmol in patients with metabolic syndrome. This may be an
early predictor of kidney damage.
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Table 1. General characteristics of all patients
Normoalbuminuria, Microalbuminuria, Macroalbuminuria,
n=18 n=35 n=17
Age (years) 63.1±9.1 61.0±10.8 65.0±11.0
BMI (kg/m2) 30.5±3.8* 33.5±6.5 35.0±3.5*
WC (cm) 95.3±5.1** 103.3±9.1** 106.1±9.5
SBP (mmHg) 153.0±14.4** 163.4±17.5** 171.7±19.6**
DBP (mmHg) 93.1±11.2 97.2±8.9** 105.1±10.5**
Total cholesterol (mmol/l) 5.9±1.3 5.4±1.4 5.3±1.2
HDL (mmol/l) 1.1± 0.2 1.0±0.3 1.0±0.3
LDL (mmol/l) 3.4±1.3 2.8±1.2 2.9±0.9
TG (mmol/l) 2.2±0.7 * 2.7±1.9 2.8±0.8*
TG/HDL index 2.2±0.1 * 3.2±0.9* 2.8±0.6
Glucose (mmol/l) 7.5±2.7 8.0±2.6 6.7±2.1
HbA1c, % 6.0±2.1 6.8±2.1 6.0±1.1
GFR (MDRD),
ml/min/1,73m2
64.9±20.5 65.4±14.5 61.7±15.3
GFR (CG), ml/min 89.1±19.6 87.1±26.1 78.9±24.1
NO, µmol 26.6±4.4 28.0±3.0 26.4±2.5
H2S, µmol 66.3±5.7* 62.2±7.9** 57.4±7.9**
Notes. *p<0.05; **p<0.01.
Figure 1. Correlation between H2S and MAU
Prospects for further research
Our works will be aimed at the development of preventive
measures for early kidney damage, decrease in MAU and
BP through the administration of hydrogen sulfide donors or
drugs elevating the level of endogenous H2S in patients with
MS.
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